Bull
$14.75
Precio del escenario
$15.550
-0.381 (-2.45%)Al cierre
ClearPoint Neuro, Inc. is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The Company provides clinical products and preclinical development services for controlled drug and device delivery. Its business consists of two components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. Its primary medical device product, the ClearPoint system, is an integrated system comprised of hardware components, disposable components, and intuitive, menu-driven software. The primary applications for the ClearPoint system are to target and guide the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, and the infusion of pharmaceuticals into the brain. It provides consulting services to its pharmaceutical and other medical technology partners.
ClearPoint Neuro Inc (CLPT) is currently a hold. The stock is priced at $15.55, which is below the analyst price targets ranging from $22 to $30. However, the company is facing significant operational challenges, with a net income loss of $11.3 million in Q2 2026 and a forward P/E ratio of 12.11, indicating potential undervaluation but also underlying financial stress.
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

ClearPoint Neuro (CLPT) Q2 2026 Earnings Call Transcript

ClearPoint Neuro Reports Q2 2026 Earnings with Strategic Updates

ClearPoint Neuro Q2 2026 Earnings Call Insights

ClearPoint Neuro Q2 Earnings Report Analysis

Aspen Receives FDA RMAT Designation for Parkinson's Therapy
ClearPoint Neuro, Inc. is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The Company provides clinical products and preclinical development services for controlled drug and device delivery. Its business consists of two components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. Its primary medical device product, the ClearPoint system, is an integrated system comprised of hardware components, disposable components, and intuitive, menu-driven software. The primary applications for the ClearPoint system are to target and guide the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, and the infusion of pharmaceuticals into the brain. It provides consulting services to its pharmaceutical and other medical technology partners. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
ClearPoint Neuro Inc (CLPT) is currently a hold. The stock is priced at $15.55, which is below the analyst price targets ranging from $22 to $30. However, the company is facing significant operational challenges, with a net income loss of $11.3 million in Q2 2026 and a forward P/E ratio of 12.11, indicating potential undervaluation but also underlying financial stress.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.